Ayalon 2025: Profit Jumped, but the Real Test Is Capital and the Savings Engine

Company Introduction

At first glance, Ayalon can look like just another insurer that enjoyed a very strong year in the capital markets. That is too shallow a reading. In 2025 the company showed three things at once: general-insurance underwriting improved, the health segment returned to meaningful profitability, and the life and savings arm started to build a larger future profit pool through higher contractual service margin and a sharp jump in investment-contract inflows. That is why total comprehensive income rose to ILS 431.2 million from ILS 259.7 million in 2024, and return on equity climbed to 33%.

What is easy to miss is that the story is still not clean. Most of the profit still comes from Ayalon’s own general-insurance business, Weshur still consumes capital and delivers weaker economics, and the latest formal solvency ratio disclosed in the annual report is for June 30, 2025 rather than year-end. In other words, the profit is already in the financials, but the capital proof point is lagging behind it.

What is clearly working now is not hard to identify. Core profit rose to ILS 564.3 million from ILS 431.4 million, the health segment moved from ILS 18.0 million to ILS 98.2 million of pre-tax comprehensive income, and investment-contract inflows jumped to ILS 1.66 billion from only ILS 268.0 million in 2024. What is still missing for a cleaner thesis is proof that the capital cushion remains comfortable after ILS 155 million of dividends, capital-instrument repayments, and ongoing support for Weshur.

That leads to the early screen. With a market cap of roughly ILS 3.8 billion, the question is no longer whether 2025 was a good year. The question is whether this is the beginning of a higher earnings tier. If it is, Ayalon starts to look like a mid-sized insurer with a strong general-insurance engine and a savings arm that is becoming more relevant. If not, 2025 will remain an excellent year that also benefited from a very supportive market backdrop and timely capital actions.

What matters before the deep dive

• Core profit, not just markets, moved sharply higher. Core profit rose by ILS 132.8 million, more than half of the total annual improvement.
• Life barely improved current earnings, but it did build future earnings stock. Core profit in life slipped slightly while net CSM rose to ILS 1.06 billion.
• Capital improved, but the report still does not provide a full year-end 2025 solvency ratio. The latest published solvency snapshot is mid-2025, with later capital actions layered on top.
• Weshur adds strategic optionality and possible synergy, but it is not the earnings engine. Its annual contribution stayed modest, while the group still had to inject more capital.

Events And Triggers

First trigger: 2025 is the first year Ayalon reports under IFRS 17 and IFRS 9, with 2024 restated accordingly. This is not a technical footnote. For insurers, that accounting shift materially changes how readers should think about profit, especially in life and health, because part of the economics moves from current earnings into the stock of future earnings.

Second trigger: In July 2025 Ayalon won the student personal-accident insurance tender. The scope is about 2.6 million students, with estimated annual premium of roughly ILS 187 million for up to three years. That is not a cosmetic event. It adds scale and exposure inside general insurance, but it will also require disciplined pricing and execution so volume does not come at the expense of economics.

Third trigger: The company is advancing toward entry into provident funds and study funds. The board has already approved the move, and the company says it is in advanced stages of preparation, but it still depends on regulatory licensing, outsourced operations, and completion of the operational setup. This is exactly the kind of signal worth tracking: the intent to broaden the savings franchise is real, but the revenue is not here yet.

Fourth trigger: The company did not wait with dividends. During 2025 it distributed ILS 155 million in three payments: ILS 30 million for 2024, ILS 75 million in August 2025, and another ILS 50 million in November 2025. The message is clear: management is more comfortable with profit quality and capital. But every shekel distributed also raises the bar for the next solvency proof point.

Fifth trigger: In January 2026 Midroog reaffirmed Ayalon’s A1.il insurance financial strength rating, kept the A3.il(hyb) rating on its subordinated instruments, and changed the outlook from stable to positive. That is an external validation that the improvement in capital and profitability is real. At the same time, a positive outlook is still a direction of travel, not a completed destination.

Sixth trigger: At the end of November 2025 the regulator required the company to update motor-property insurance tariffs. Ayalon says the impact should not be material, but analytically it is a useful reminder that the company’s main engine is still exposed to competition and regulation. Not every underwriting gain can simply be projected forward in a straight line.

Efficiency, Profitability And Competition

The core story of 2025 is not just “high profit.” The core story is high profit built from both operating improvement and strong capital markets. If one of those two engines had been missing, the year still would have been good, but not nearly as strong.

What Really Drove Earnings

Core profit rose from ILS 431.4 million to ILS 564.3 million. That is the center of gravity. Excess financial margin moved from a loss of ILS 22.8 million to a profit of ILS 74.3 million, which helped a great deal as well. But anyone who looks only at the bottom line will miss that the improvement rested on a broader base: Ayalon general insurance added ILS 101.0 million of pre-tax comprehensive income, health added ILS 80.2 million, life and savings added ILS 13.3 million, while Weshur barely moved.

In other words, 2025 was not a year in which one segment dragged the whole group upward. The earnings base broadened, even if the weight of that base remained uneven.

General Insurance Still Carries The Group

Even after all the talk about savings, digital, and CSM, Ayalon’s real earnings engine is still general insurance. Ayalon itself generated ILS 391.2 million of pre-tax comprehensive income in that segment, versus only ILS 17.5 million at Weshur. Within general insurance, the strongest leg is “other,” meaning lines such as professional liability, contractors, guarantees, and other property, with core profit of ILS 213.7 million. That matters because it shows the improvement is not just a motor story.

Motor liability improved mainly because of better claims development from prior accident years. Motor property improved more moderately on a full-year basis, with help from higher-exposure premium and better prior-year claims development. In other lines, the improvement came from both better sales and a better portfolio mix. That is the kind of improvement the market tends to trust more, because it is not purely a lucky market year or a rate curve effect.

The nuance is important. In motor property, the combined ratio did not collapse to unusually low levels. At Ayalon it stayed at 90% gross and 91% net, almost unchanged from 2024. That means the profit jump did not come from some dramatic underwriting reset in motor property, but from a mix of better claims management, a better book, and strong profitability in other lines. That is healthier, but it also means the story should not be reduced to “motor saved the year.”

At Weshur, the picture is less clean. Core profit in general insurance fell from ILS 27.7 million to ILS 19.3 million, and profitability in motor liability and motor property deteriorated partly because reinsurance terms got worse. That is an important yellow flag. It means the group synergy story has not yet translated into clean economics at the subsidiary level.

Health Improved, But Not In A Straight Line

The health segment moved from ILS 18.0 million to ILS 98.2 million of pre-tax comprehensive income. That is a very large swing. It came mainly from higher CSM release in private medical-expense and critical-illness policies, more new business, and the fact that 2024 carried a negative burden in group health that did not repeat at the same scale.

But it is important to stop there and not extrapolate too fast. In the fourth quarter, health core profit was essentially flat at minus ILS 0.2 million, while the segment’s positive total result came mainly from financial margin. So anyone who takes the ILS 98 million from 2025 and turns it into a 2026 run rate is making life too easy for themselves. The improvement is real, but it still has to prove smoother quarterly durability.

Life And Savings Tell A Different Story

In life and long-term savings, pre-tax comprehensive income rose from ILS 96.4 million to ILS 109.7 million, but core profit actually edged down from ILS 102.1 million to ILS 100.3 million. That is a critical point. The story here is not a sharp improvement in current earnings. The story is the build-up of future earnings stock.

Net CSM rose to ILS 1.058 billion from ILS 1.014 billion at the end of 2024. The company released roughly ILS 171 million of gross CSM in 2025, but added new business at 122% of that release pace. In growth products, the ratio reached 233%. That is a strong signal that the company is not merely harvesting old profit pools. It is refilling them.

The second signal comes from investment contracts: inflows surged to ILS 1.66 billion from ILS 268 million in 2024. That is not a side note. It shows Ayalon was able to pull in new savings money at a very different pace. If that translates into stable managed assets, fee income, and future CSM, then 2025 may later look like the year in which the savings leg moved from possibility to actual engine.

What The Market May Miss On First Read

In the fourth quarter, total comprehensive income rose 75% to ILS 111.3 million, but excess financial margin actually fell from ILS 61.0 million to ILS 53.6 million. Anyone reading only the headline could conclude that the quarter was once again carried by markets. In practice, what held the quarter together was core profit of ILS 116.5 million versus ILS 37.7 million a year earlier. That makes the fourth quarter one of the most important signals in the report: even without another step up in financial margin, the company generated a much wider operating base.

Cash Flow, Debt And Capital Structure

For an insurer, accounting cash flow matters, but it does not sit at the center the way it would for an industrial or retail business. Capital, solvency, and the ability to absorb volatility without raising money under pressure matter more. Still, even on the all-in cash picture, there is no immediate stress here.

On an all-in cash basis, meaning after the period’s actual cash uses, the company generated ILS 309.7 million of operating cash flow in 2025, used ILS 117.6 million for investing activity, and used a net ILS 54.5 million for financing activity. Year-end cash increased by ILS 137.6 million to ILS 846 million. So even after ILS 155 million of dividends, the cash position did not shrink. It expanded.

But that is not the decisive lens. The decisive lens is capital headroom. Equity attributable to shareholders rose to ILS 1.521 billion from ILS 1.094 billion at the end of 2024. That increase came from ILS 431.2 million of total comprehensive income, ILS 141.5 million of share issuance, ILS 7.7 million of option proceeds, and ILS 155 million of dividends paid out.

Where The Real Capital Test Sits

The most important number in the capital story is not ILS 1.52 billion of equity. The important number is how much capital headroom remains above regulatory requirements. And here there is a gap readers need to respect: the annual report itself provides Ayalon’s solvency ratio only as of June 30, 2025.

At that date, the solvency ratio stood at 129% without transitional relief and 136% with transitional relief, after the effect of material capital actions that took place after the calculation date. That is a meaningful improvement versus the end of 2024. But on December 31, 2025 the company also repaid a subordinated instrument of ILS 40 million, which management says should reduce the solvency ratio by roughly 2 percentage points, and that repayment is not yet included in the published ratio.

That means 2025 clearly tells a story of higher capital, but it still does not give the market a full updated year-end solvency reading. Anyone saying today that Ayalon is sitting on a very wide capital cushion is leaning partly on extrapolation. There is improvement, there is headroom, and there is supportive external validation from Midroog. But the complete numerical proof still has to arrive.

The Dividend Is Both A Strength Signal And A Test

In December 2024 the company adopted a policy under which it intends to distribute at least 40% of annual comprehensive income, as long as it remains above the solvency target set by the board. That is a relatively aggressive stance for a company that not long ago was much more focused on building capital than distributing it.

The positive side is obvious. Companies do not adopt a policy like that without greater confidence in profit quality and capital. The other side matters just as much: from this point onward, every strong profit report will also be judged through the lens of distribution capacity. That is precisely why 2026 becomes a proof year. If profit and capital keep rising, the policy will look like a stamp of confidence. If solvency headroom tightens, the same policy will start to weigh on the story.

Weshur Still Sits On Group Capital

This is one of the less obvious points in the headline narrative. Weshur’s solvency ratio stood at 103% in June 2025 after capital actions, versus 101% at the end of 2024. That is progress, but it is not a level that invites comfort. During 2025 Ayalon injected ILS 20 million of Tier 2 capital and ILS 20 million of equity into Weshur, and after the balance sheet date it approved another ILS 16 million of equity support.

In other words, the Weshur acquisition may well strengthen distribution, digital capability, and group presence in general insurance over time, but right now it is still using the group’s capital cushion. That does not invalidate the move. It just requires the story to be written correctly: this is strategic optionality with a real capital cost attached.

The External Signal

Midroog moved Ayalon’s outlook to positive because of better profitability, asset quality, and capital adequacy. That matters because it is an external signal rather than management framing. At the same time, the same report also points to what has not disappeared: a relatively weak liquidity profile because of the business mix, and high exposure to collectives and large insureds amounting to roughly 43% of gross earned premiums in 2024. That is the most accurate way to describe the tension inside Ayalon: capital has improved, but the risk base still requires discipline.

Forecasts And Forward View

First finding: 2026 looks like a proof year, not a comfort year. The 2025 profit is strong, but the market still needs to see that capital is not only better on paper but remains wide enough after distributions, capital repayments, and support for Weshur.

Second finding: The savings engine improved more than the current earnings line in life. So the next reports will have to show that the jump in investment-contract inflows and the rebuild in CSM actually create a larger future earnings base, rather than just one strong sales year.

Third finding: Ayalon’s own general-insurance business is still the anchor. If motor and non-motor underwriting stay strong even in a less supportive pricing environment, the thesis becomes much more defensible.

Fourth finding: Weshur needs to move from consuming capital to making a more visible economic contribution. Otherwise it will remain a strategically interesting story with too high a capital cost attached.

A Proof Year With Two Tests

The first test is capital. The company’s internal target is a minimum 107% capital ratio without transitional relief, rising gradually to 110% by 2032. Based on June 2025, it has comfortable headroom above that level. But what the market really needs to see is that this was not a one-off window created by a good capital raise and strong markets.

The second test is business quality. Ayalon clearly built a more interesting savings leg this year, but it is still not replacing general insurance as the main earnings engine. So over the next 2 to 4 quarters the market will watch three things at the same time: whether investment-contract inflows remain high, whether CSM continues to build faster than release, and whether core profitability in general insurance holds up as competition becomes tougher again.

What Needs To Happen In Savings

Investment-contract inflows of ILS 1.66 billion are unusually strong. If this turns out to be a one-off sales spike driven mainly by momentum, the market will struggle to pay a high multiple for it. If, on the other hand, the company shows that the new money sticks, that investment performance remains strong, and that the move into provident and study funds actually happens, then 2025 may later look like the opening year of a broader savings franchise.

What Needs To Happen In General Insurance

The demand here is simpler: maintain profitability without relying on unusually favorable tailwinds. Ayalon’s general-insurance business already showed in 2025 that it can earn not only in motor, but also in the broader non-motor book. Now it has to show that this continues while motor-property tariffs are being revisited and while Weshur tries to grow again through the 2026 state-employee motor tender.

What Management Is Signaling Without Saying It Directly

The most important signal is that Ayalon is now speaking and acting more like a group that wants a broader savings franchise, not just a traditional insurer preserving its legacy book. The preparation for provident funds, the emphasis on investment returns in savings products, the jump in investment contracts, and the willingness to distribute dividends at the same time all point in that direction.

There is also a secondary signal. When the company distributes ILS 155 million, improves its rating outlook, and continues to inject capital into Weshur, it is effectively saying that the group believes it can build a new engine, support a subsidiary story, and still reward shareholders. That is an ambitious message. 2026 will have to confirm it.

Risks

The first risk is timing mismatch in capital proof. The profit already belongs to 2025, but the full year-end solvency reading does not. As long as that picture is incomplete, the market is still working with a partial capital map.

The second risk is sensitivity to capital markets and rates. 2025 enjoyed excess financial margin of ILS 74.3 million versus a loss of ILS 22.8 million in 2024. That is good, but it is also a reminder of how much reported economics can still depend on the financial backdrop. In the fourth quarter, excess financial margin was already lower year over year despite strong earnings overall.

The third risk is exposure to large collectives and insureds. According to Midroog, this represented roughly 43% of gross earned premiums in 2024. That can limit risk-adjusted pricing and increase volatility if a major client moves or a whole line weakens.

The fourth risk is health and regulation. Health was the star segment of the year, but it is also exposed to pricing pressure, regulation, and rising medical costs, especially in products where actual medical expense tends to rise faster than tariff assumptions.

The fifth risk is Weshur. The subsidiary still has not proven that it can generate a sufficiently attractive return on the capital the group keeps allocating to it. If it remains too close to the solvency floor, its strategic contribution will continue to come with friction.

The sixth risk is legal and contingent exposure. The auditors drew attention to contingent liabilities. Without one clean number that can be translated easily into earnings, the market cannot haircut it neatly, but it is still not a line that should be dismissed as mere legal background noise.

Short Interest Read

Against the backdrop of a strong share performance in recent years, short-interest data does not point to a crowded bearish setup. As of March 27, 2026, short float stood at 0.53% and SIR stood at 0.95. Both are below the sector averages of 0.86% and 1.952, respectively.

That does not prove the market is fully comfortable. It means that whatever skepticism exists is not currently sitting in a pronounced short position. So another positive surprise would likely come more through a change in how the market reads earnings quality and capital strength, not through a technical squeeze.

Conclusions

Ayalon reaches the end of 2025 with a stronger thesis than it had at the start of the year. What supports that thesis now is the combination of real underwriting improvement, a stronger savings build, and a capital position that looks better. The main blocker is that the market still needs a full updated solvency proof point, while also seeing Weshur stop leaning on group capital. In the short to medium term, what will shape the market’s interpretation is less the profit headline itself and more whether 2026 confirms that this is a new earnings tier rather than a convenient peak year.

Current thesis in one line: Ayalon finished 2025 as a stronger insurer, with a general-insurance arm that produces earnings and a savings arm that is starting to build the future, but it still has to prove that capital headroom remains wide after distributions and support for Weshur.

What changed versus the earlier reading of the company? Ayalon no longer looks only like an insurer that depends mainly on general insurance and favorable markets. 2025 shows a savings engine that is taking shape and a health segment that can become a meaningful contributor. But precisely because the company looks stronger, the capital proof threshold is now higher.

Counter-thesis: Too much of the 2025 improvement still depends on strong capital markets and a favorable capital window, while the full year-end solvency ratio has not yet been published and Weshur still needs capital. If financial margin softens and underwriting does not keep improving, 2025 could end up looking like a peak year rather than a new base.

What could change the market’s interpretation in the short to medium term? A strong updated solvency report, proof that investment-contract inflows were not a one-off spike, and clearer improvement in Weshur’s profitability. On the other side, weaker health profitability, pricing pressure in motor, or more capital injections into Weshur would quickly change the tone.

Why this matters: if Ayalon is truly moving from an insurer that had a very good year to a group that is broadening its earnings engines without losing capital discipline, then the underlying business quality is improving, not just the reported bottom line.

Over the next 2 to 4 quarters, the thesis strengthens if the company shows comfortable solvency after distributions and repayments, maintains good underwriting profitability in general insurance and health, and proves that the jump in investment-contract inflows is translating into a larger future earnings base. It weakens if capital turns out to be less comfortable than the mid-2025 data implied, if health profitability proves too temporary, or if Weshur continues to consume capital without generating adequate economic contribution.